Gut microbiota disorders cause type 2 diabetes mellitus and homeostatic disturbances in gut-related metabolism in Japanese subjects

Kazunori Adachi,† Tomoya Sugiyama,† Yoshiharu Yamaguchi,† Yasuhiro Tamura,† Shinya Izawa,† Yasutaka Hijikata,† Masahide Ebi,† Yasushi Funaki,† Naotaka Ogasawara,† Chiho Goto,‡ Makoto Sasaki†,* and Kunio Kasugai†

†Department of Gastroenterology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan
‡Department of Health and Nutrition, Faculty of Health and Human Life, Nagoya Bunri University

(Received 7 November, 2018; Accepted 20 December, 2018; Published online 23 March, 2019)

Few studies have investigated the host-microbe metabolic axis in people with type 2 diabetes mellitus (T2DM). This study aimed to determine and compare the nutrient intakes and metabolic markers and to elucidate the relationships among these factors in Japanese T2DM patients and control individuals. Fifty-nine Japanese T2DM patients and 59 matched healthy control individuals participated in this study. We examined the differences regarding the participants’ dietary habits, microbiota, and fecal short-chain fatty acids, and analyzed the relationships between the gut microbiota and blood metabolic markers in the T2DM patients and the control subjects. The T2DM patients consumed more carbohydrates, and had lower fecal propionate and butyrate concentrations, larger fecal populations of *Bifidobacterium* spp. and bacteria of the order *Lactobacillales*, and smaller fecal *Bacteroides* spp. populations than the control individuals. In the T2DM patients, the level of *Bifidobacterium* spp. correlated negatively with the carbohydrate intake and the level of bacteria of the order *Lactobacillales* correlated negatively with the protein intake. T2DM patients have gut dysbiosis that may contribute to disease onset and influence its prognosis. Furthermore, homeostatic disturbances in the gut-related metabolism may underlie the pathogenesis of T2DM.

**Key Words:** gut dysbiosis, short-chain fatty acid, type 2 diabetes, dietary habit, *Bifidobacterium* spp.

The human gut hosts trillions of microorganisms, and these include over $10^{13}$ bacteria that belong to 1,000 species. The size of this microbial organ’s genome, which is called the microbiome, exceeds that of the human nuclear genome by 100-fold, and it provides additional biological and metabolic functions that maintain homeostasis within the body.

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is caused by deficiencies in insulin production, which are the consequence of the exhaustion of pancreatic beta cell function after insulin resistance has been established. Data from the World Health Organization indicate that about 382 million people worldwide had T2DM in 2013 and that about 592 million people will have T2DM by 2035. In addition, 85% of the premature deaths associated with metabolic syndrome occur in developing countries, and about 80% of these deaths are associated with diabetes. Genetic and environmental factors contribute to the pathogenesis of diabetes, particularly T2DM. The findings from recent studies have suggested that the gut microbiota in T2DM patients differs from that in healthy people, and that the gut microbiota is an important environmental factor in diabetes development. Furthermore, compositional changes in particular species of the bacterial genus *Bacteroides* in the intestines of humans and animal models may cause many chronic diseases, including diabetes, obesity, inflammatory bowel disease, cancer, and cardiovascular disease. However, the microbiota of the gut differs according to species, geographic location, age, the gender composition of the population, and dietary habits. Several changes in the gut microbiota were associated with age and sex in healthy Japanese subjects.

Short-chain fatty acids (SCFAs), which arise mainly from bacterial fermentation in the gut, can provide energy and they may be involved in lipid and glucose metabolism, which suggests that they may influence metabolic risk factors. We have reported associations between the intestinal microbiota, and, hence, gut SCFAs, and the metabolic markers in and dietary habits of patients with T2DM. However, differences between healthy control individuals and patients with T2DM regarding the associations between fecal SCFAs and metabolism have not yet been described. This study aimed to determine and compare the nutrient intakes, metabolic markers, including those associated with glucose tolerance, lipid metabolism, and hepatic function, fecal microbiota, and the SCFAs, and to elucidate the relationships among these factors in Japanese T2DM patients and control individuals.

**Methods**

This study was conducted according to the World Medical Association Declaration of Helsinki and was approved by the ethics review committee at Aichi Medical University’s School of Medicine in Japan on July 3, 2015 (registration number was 15-019). Written informed consent was obtained from each individual before study enrollment. We recruited Japanese patients who were diagnosed with T2DM using the Japan Diabetes Society’s criteria, and who had glycated hemoglobin (HbA1c) levels of 6.2–7.9% at screening, had received stable doses of medication for at least 1 month, and had stable diabetes for at least 3 months, that is, a change in the HbA1c level of <1.0%. The patients received nutritional guidance from a dietician, and they were eligible to receive diet therapy. Age- and sex-matched control individuals who did not have histories of diabetes or cancer were recruited to participate in the study. Individuals with a history of gut resection were excluded from the study. Fasting blood and fecal samples were collected and stored at −80°C until they were analyzed. The fecal microbiota was analyzed using the terminal-
restriction fragment length polymorphism (T-RFLP) technique. A self-administered short food frequency questionnaire (FFQ) was used to evaluate the subjects’ nutrient intakes.\(^{(15)}\)

**Fecal DNA extraction.** The fecal samples (500 mg) were washed three times with sterile distilled water, suspended in 4 M guanidinium thiocyanate, 100 mM Tris-HCl (pH 9.0), and 40 mM EDTA, and digested with glass beads using a bead beating technique (Bio Spec Products Inc., Bartlesville, OK). Thereafter, the DNA was extracted from the bead-treated suspension using benzyl chloride, as described by Zhu et al.\(^{(14)}\) The DNA extract was then purified using a GFX\(^{TM}\) PCR DNA and Gel Band Purification Kit (GE Healthcare, Chicago, IL). The final concentration of each DNA sample was adjusted to 10 ng/µl.

**Terminal-restriction fragment length polymorphism technique.** The 16S rDNA amplification and its digestion with restriction enzymes, the size fractionation of the terminal restriction fragments (T-RFs), and the analysis of the T-RFLP data were performed according to the protocol described by Nagashima et al.\(^{(15)}\) Briefly, a polymerase chain reaction (PCR) was performed using a total fecal DNA (10 ng/µl) sample and an Escherichia coli-specific primer pair for 16S rDNA amplification (16F: 5'-GTC CAG AGG CCA GGT ATT C-3' for E. coli positions 516-532 and 151F: 5'-GGTTACCTTGTTACGACTT-3' for E. coli positions 1510-1492). The 5'-ends of the forward primers were labeled with 6'-carboxyfluorescein, which was synthesized by Applied Biosystems Inc. (Foster City, CA). The amplified 16S rDNA genes were purified using a GFX\(^{TM}\) PCR DNA and Gel Band Purification Kit (GE Healthcare) and dissolved in 30 µl distilled water. The purified PCR products (2 µl) were digested with Bsu I (10 U) at 55°C for 3 h. The lengths of the T-RFs were determined using an ABI Prism\(^{®}\) 3100xl genetic analyzer (Applied Biosystems Inc.) in GeneScan mode and standard size markers (MapMarker\(^{®}\) X-Rhodamine Labeled 50–1,000 bp; BioVentures, Inc., Murfreesboro, TN). The fragment sizes were estimated using the Local Southern Method sizing algorithm (GeneMapper\(^{®}\); Applied Biosystems Inc.).

The T-RFs were divided into 30 operational taxonomic units (OTUs) according to the method described by Nagashima et al.\(^{(15)}\) Each OTU was quantified as a percentage of the total OTU area, and they were expressed as the peak percent area under the curve (%). Cluster analyses that were based on Bsu I T-RFLP patterns, were performed using GeneMaths software (Applied Maths NV, Sint-Martens-Latem, Belgium).

**Fecal short-chain fatty acid analysis.** To analyze the SCFAs, feces (0.1 g) were placed in a 2.0 ml tube with zirconia beads and suspended in a 0.1 M perchloric acid solution with 3% phenol. The samples were heated at 80°C for 15 min, vortexed at 5 m/s for 45 s using a FastPrep 24 homogenizer (MP Biomedicals, Santa Ana, CA), and centrifuged at 15,350 x g for 10 min. The supernatant was filtered using a 0.45 µm filter (DISMIC-13HP; Advantec Co., Ltd., Tokyo, Japan). The acetic acid, propionic acid, butyric acid, isobutyric acid, succinic acid, lactic acid, formic acid, valeric acid, and isovaleric acid levels were determined using high-performance liquid chromatography (Prominence; Shimadzu Corporation, Kyoto, Japan) and a post-column reaction detection system, comprising a detector (CDD-10A; Shimadzu Corporation), two columns arranged in tandem (Shim-pack SCR-102(H), 300 mm x 8 mm ID; Shimadzu Corporation), and a guard column (Shim-pack SCR-102(H), 50 mm x 6 mm ID; Shimadzu Corporation). The system included a mobile phase that comprised 5 mM p-toluenesulfonic acid, and a reaction solution that comprised 5 mM p-toluenesulfonic acid, 100 µM EDTA, and 20 mM Bis-Tris. The flow rate was 0.8 mll/min and the oven temperature was 45°C. The detector cell temperature was maintained at 48°C.

**Self-administered short food frequency questionnaire.** The FFQ inquired about the subjects’ habitual dietary intakes of 47 foods/recipes during the previous year and their intake frequencies, which were categorized as never or seldom, 1–3 times/month, 1–2 times/week, 3–4 times/week, 5–6 times/week, once/day, twice/day, and >3 times/day. The serving sizes were recorded for staple foods, including rice, noodles, and bread.

**Calculation of nutrient intakes.** We computed the average daily consumptions of energy and selected nutrients using the information from the FFQ and a lifestyle questionnaire, which included information about the consumption of alcohol. Based on a regression analysis, selected nutrients were adopted as dependent parameters, and the foods/food groups consumed, intake frequencies, portion sizes in grams, which were based on values from a database or typical/standard values from the literature, and the nutritional content/100 g of the foods/food groups that were listed in composition tables or in model recipes, were considered to be independent variables.\(^{(16–18)}\)

**Statistical analyses.** All of the statistical analyses were performed using JMP statistical software, ver. 11.2.1 for Windows (SAS Institute Inc., Cary, NC). The normally distributed data are expressed as the means and the standard deviations, and the data with skewed distributions are presented as the medians (interquartile ranges). Spearman’s correlation coefficient was used to determine associations between the abundance of the fecal bacteria and the SCFAs, food intakes, and the clinical parameters. A value of p<0.05 was considered statistically significant.

**Results**

**Patients’ characteristics and food intakes.** Fifty-nine patients with T2DM, comprising 34 men and 25 women whose ages ranged from 57.5 years to 69 years (median 64 years), and 59 control individuals, comprising 34 men and 25 women whose ages ranged from 59 years to 69 years (median 62 years), were enrolled to participate in this study. Table 1 presents the characteristics of the patients with T2DM and the control individuals. The groups did not differ significantly regarding the average body mass index (BMI), and the high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), free fatty acid (FFA), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), γ-glutamyl transferase (γ-GTP), and aspartate aminotransferase (AST) levels. The T2DM patients had higher fasting blood glucose (FBG), HbA1c, insulin, and alanine aminotransferase (ALT) levels, and homeostasis model of insulin resistance (HOMA-IR) values, than the control subjects. Based on the data from the FFQ, the mean total energy intakes were similar in the T2DM patients (1,692 ± 380 kcal/day) and the control subjects (1,705 ± 345 kcal/day). The ratio of fat intake and protein intake to total energy intake in the T2DM patients and in the control subjects was 23.2 ± 5.3% vs 24.7 ± 6.3%, and 13.2 ± 2.2% vs 12.7 ± 1.7%, respectively; there were not significantly different between the two groups. The mean carbohydrate intake as a proportion of the total energy intake was significantly higher in the T2DM patients than that in the control subjects (57.5 ± 5.2% vs 55.4 ± 5.5%, p<0.05). The number of the participants who consumed yogurt at least once a week was significantly lower in the T2DM patient group (n = 27) than in the control group (n = 41) (p=0.01).

**Cluster analysis.** Figure 1 showed the dendrogram of the fecal bacteria structure in the T2DM patients and the control individuals. Two separate clusters were evident that corresponded to the T2DM patients and the control subjects.

**Terminal-restriction fragment length polymorphism analysis of the fecal samples.** Table 2 shows the population of total sequences and the detection rate in fecal bacteria of the T2DM patients and the control subjects. The population of fecal bacteria for Bifidobacterium spp. (25.7% vs 5.5%, p<0.01) and for order Lactobacillales (17.3% vs 1.6%, p<0.01) were significantly higher in the fecal samples from the T2DM patients than those in the fecal samples from the control group. The population of fecal bacteria for Bacteroides spp. was significantly lower in the T2DM patient group than in the control group (12.4% vs 50.6%, p<0.01). The population of fecal bacteria for fecal Clostridium

232
doi: 10.3164/jcnb.16-101
©2019 JCBN
cluster IV, *Clostridium* cluster XI, *Clostridium* subcluster XIVa, *Clostridium* cluster XVIII, and *Prevotella* spp. were similar in both groups. In the T2DM patient group, the *Clostridium* cluster IV (83.1% vs 96.6%, *p* < 0.05), *Clostridium* cluster XI (32.2% vs 54.2%, *p* < 0.05), and *Clostridium* cluster XVIII (44.1% vs 86.4%, *p* < 0.01) detection rates were significantly lower than those in the control subjects.

### Fecal short-chain fatty acid and pH levels.

The total SCFA levels and the fecal pH levels were similar in the two groups (Table 3). The T2DM patients had lower fecal propionate (1.32 mg/g vs 1.81 mg/g, *p* < 0.05) and butyrate (1.03 mg/g vs 1.48 mg/g, *p* < 0.01) levels and a higher fecal succinate level (0.14 mg/g vs 0.07 mg/g, *p* < 0.01) than those in the control subjects. The valerate detection rate was lower in the T2DM patients than that in the control subjects (74.6% vs 94.8%, *p* < 0.01). The succinate detection rate was higher in the T2DM patients than that in the control subjects (59.3% vs 25.7%, *p* < 0.01).

### Relationships among the fecal microbiota, the short-chain fatty acids, the food intakes, and metabolism.

Table 4 shows the relationships among the fecal microbiota, the SCFAs, the food intakes, and metabolism in the T2DM patients and the control subjects. The level of fecal *Bifidobacterium* spp. correlated negatively with the carbohydrate intake in the T2DM patients (*r* = −0.420, *p* = 0.001), but not in the control subjects. In the T2DM patients, the level of fecal bacteria of the order *Lactobacillales* correlated negatively with the protein intake (*r* = −0.275, *p* < 0.05 vs control, **p* < 0.01 vs control. M, male; F, female; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment for insulin resistance; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride; FFA, free fatty acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, γ-glutamyl transferase; SU, sulfonylurea; α-Gl, α-glucosidase inhibitor.

### Table 1. Characteristics of the study subject

| Type 2 diabetic patients (n = 59) | Control subjects (n = 59) |
|----------------------------------|--------------------------|
| SEX, n                           |                          |
| Male                             | 34                       | 34                       |
| Female                           | 24                       | 25                       |
| Age                              | 64.0 (57.5–69.0)         | 62.0 (59.0–69.0)         |
| 30–39, M : F                     | 2 : 0                    | 2 : 0                    |
| 40–49, M : F                     | 0 : 1                    | 0 : 1                    |
| 50–59, M : F                     | 10 : 5                   | 10 : 5                   |
| 60–69, M : F                     | 12 : 15                  | 12 : 15                  |
| 70–79, M : F                     | 10 : 4                   | 10 : 4                   |
| Body mass index, kg/m²           | 23.0 (20.4–25.6)         | 22.7 (20.8–24.3)         |
| FBG, mg/dl                       | 144.7 ± 27.1**           | 96.3 ± 10.3              |
| HbA1c, %                         | 7.1 (6.8–7.6)**          | 5.5 (5.3–5.7)            |
| Insulin, μU/ml                   | 7.2 (4.9–11.1)*          | 5.3 (3.1–7.5)            |
| HOMA-IR                          | 2.7 (1.7–4.5)**          | 1.2 (0.7–1.7)            |
| TC, mg/dl                        | 208.6 ± 32.0             | 211.4 ± 35.0             |
| HDL, mg/dl                       | 57.7 ± 16.9              | 60.8 ± 15.9              |
| LDL, mg/dl                       | 124.7 ± 29.0             | 131.2 ± 28.9             |
| TG, mg/dl                        | 123.3 ± 47.7             | 110.7 ± 61.8             |
| FFA, Eq/L                        | 645.4 ± 436.3            | 500.5 ± 248.0            |
| AST, U/L                         | 21.0 (20.0–24.5)         | 21.0 (19–24.5)           |
| ALT, U/L                         | 21.0 (17.0–28.0)*        | 18.0 (14.0–23.0)         |
| γ-GTP, U/L                       | 22.0 (17.5–32.0)         | 24.0 (16.0–38.5)         |
| Medication for diabetes, n       | 56                       | 0                       |
| No medication                    | 3                        | 59                      |
| Insulin only or with oral therapy| 11                       | 0                       |
| Oral therapy only                | 45                       | 0                       |
| SU                               | 34                       | 0                       |
| Metformin                        | 17                       | 0                       |
| α-Gl                             | 27                       | 0                       |
| Thiazolidine                     | 15                       | 0                       |
| Medication for other diseases, n | 45                       | 18                      |
| No medication                    | 14                       | 41                      |
| Antihypertensive drugs           | 28                       | 9                       |
| Lipid-lowering drugs             | 27                       | 10                      |
| Total energy intake, kcal/day    | 1,692 ± 380              | 1,705 ± 345              |
| Carbohydrate intake, %           | 57.5 ± 5.2*              | 55.4 ± 5.5               |
| Fat intake, %                    | 23.2 ± 5.3               | 24.7 ± 6.3               |
| Protein intake, %                | 13.2 ± 2.2               | 12.7 ± 1.7               |
| Participants taking yogurt at least once a week, n | 27** | 41 |
Fig. 1. Dendrogram of the fecal bacteria structure in the T2DM patients and control subjects. T-RFLP patterns by *BslI* digestions were analyzed using the software GeneMaths (Applied Maths), and the Person similarity coefficient analysis and unweighted pair-group method with arithmetic means were used to establish the type of dendrogram. Open circle, control individuals; closed circle, T2DM patients.

Table 2. Terminal restriction fragment length polymorphism analysis of the feces

|                         | Type 2 diabetic patients | Control subjects |
|-------------------------|--------------------------|------------------|
|                         | Population, % of total sequences | Detection rate, % | Population, % of total sequences | Detection rate, % |
| *Bifidobacterium* spp.  | 25.7 (12.4–38.5)**       | 94.9             | 5.5 (1.5–12.0)                  | 88.1            |
| Order *Lactobacillales* | 17.3 (5.7–29.3)**        | 89.8             | 1.6 (0.8–3.5)                  | 91.5            |
| *Bacteroides* spp.      | 12.4 (4.8–15.8)**        | 98.3             | 50.6 (42.2–55.1)               | 100             |
| *Clostridium* cluster IV| 3.4 (1.3–13.4)           | 83.1*            | 6.4 (3.4–8.7)                  | 96.6            |
| *Clostridium* cluster XI| 0.0 (0.0–1.5)            | 32.2*            | 0.4 (0–1.2)                    | 54.2            |
| *Clostridium* subcluster XIVa | 17.0 (8.0–29.0)         | 98.3             | 15.3 (11.2–19.3)               | 100             |
| *Clostridium* cluster XVIII | 0.0 (0.0–4.9)          | 44.1**           | 1.1 (0–2.4)                    | 86.4            |
| *Prevotella* spp.       | 0.0 (0.0–0.0)            | 11.9             | 0.0 (0.0–0.0)                  | 22.0            |
| Others                  | 9.2 (6.4–14.8)**         | 94.9             | 6.2 (4.7–8.6)                  | 100             |

The data presented are the medians (interquartile ranges), unless otherwise indicated. *p<0.05 vs control, **p<0.01 vs control.

Table 3. Fecal short-chain fatty acid and the pH levels

|                         | Type 2 diabetic patients | Control subjects |
|-------------------------|--------------------------|------------------|
|                         | Fecal SCFAs (mg/g) and pH | Detection rate, % | Fecal SCFAs (mg/g) and pH | Detection rate, % |
| Total SCFAs             | 7.05 (4.85–9.53)         | 100              | 8.15 (6.44–9.81)           | 100              |
| Acetate                 | 3.71 (2.53–4.73)         | 96.6             | 4.31 (2.67–5.80)           | 100              |
| Propionate              | 1.32 (0.83–3.72)*        | 96.6             | 1.81 (1.26–2.26)           | 96.6             |
| Butyrate                | 1.03 (0.41–1.54)**       | 86.4             | 1.51 (0.93–1.98)           | 100              |
| Valerate                | 0.61 (0.06–0.99)         | 74.6**           | 0.40 (0.24–0.72)           | 94.8             |
| Succinate               | 0.14 (0.00–0.11)**       | 59.3**           | 0.07 (0.00–0.06)           | 25.7             |
| Formate                 | 0.00 (0.00–0.00)*        | 6.8              | 0.00 (0.00–0.00)           | 0                |
| Lactate                 | 0.17 (0.00–0.00)         | 15.3             | 0.00 (0.00–0.00)           | 5.1              |
| pH                      | 6.74 ± 0.75             | 100              | 6.85 ± 0.85                | 100              |

The data presented are the medians (interquartile ranges), unless otherwise indicated. *p<0.05 vs control, **p<0.01 vs control. SCFA, short-chain fatty acid.
negatively with the HOMA-IR value in the T2DM patients ($r_p = 0.043$). The level of fecal correlated negatively with the total energy intake ($r_p = 0.021$), and negatively with the TC level ($r_p = 0.031$), but not in the control subjects. In the T2DM patients, the fecal propionate level correlated positively with the insulin level ($r = 0.300$, $p = 0.022$), and in the control subjects, it correlated negatively with the LDL-C ($r = 0.303$, $p = 0.020$), FFA ($r = 0.340$, $p = 0.008$), and TC ($r = 0.325$, $p = 0.012$) levels. The level of fecal Prevotella spp. correlated negatively with the HbA1c level in the T2DM patients ($r = 0.271$, $p = 0.011$), and with the FFA level in the control subjects ($r = 0.258$, $p = 0.049$). In the T2DM patients, the level of other fecal bacteria correlated positively with the ALT ($r = 0.311$, $p = 0.011$), AST ($r = 0.258$, $p = 0.049$), and $\gamma$-GTP ($r = 0.300$, $p = 0.021$) levels, correlations that were not apparent in the control subjects.

The total SCFA level in the feces correlated negatively with the protein intake in the T2DM patients ($r = -0.275$, $p = 0.038$), a correlation that was not apparent in the control subjects. The fecal acetate level correlated negatively with the protein intake ($r = -0.269$, $p = 0.045$), and the control subjects, it correlated negatively with the HDL-C ($r = -0.284$, $p = 0.034$) and with the FFA level in the control subjects ($r = -0.281$, $p = 0.031$). In the T2DM patients, the level of fecal Clostridium cluster XI correlated positively with the TC level ($r = 0.301$, $p = 0.021$), protein intake ($r = 0.362$, $p = 0.005$), and the HDL-C level ($r = 0.277$, $p = 0.034$) in the T2DM patients, and in the control subjects, the Clostridium cluster XI level correlated positively with the insulin level ($r = 0.408$, $p = 0.001$), HOMA-IR value ($r = 0.413$, $p = 0.001$), and the FBG level ($r = 0.270$, $p = 0.038$), and it correlated negatively with the FFA level ($r = -0.281$, $p = 0.031$). The level of fecal Clostridium cluster XIVa correlated positively with the TC level ($r = 0.321$, $p = 0.014$), and in the control subjects, it correlated negatively with the total energy intake ($r = -0.264$, $p = 0.043$). The level of fecal Clostridium cluster XVIII correlated negatively with the HOMA-IR value in the T2DM patients ($r = -0.300$, $p = 0.022$), and in the control subjects, it correlated negatively with the LDL-C ($r = -0.303$, $p = 0.020$), FFA ($r = -0.340$, $p = 0.008$), and TC ($r = -0.325$, $p = 0.012$) levels. The level of fecal Prevotella spp. correlated negatively with the HbA1c level in the T2DM patients ($r = -0.271$, $p = 0.011$), and with the FFA level in the control subjects ($r = -0.258$, $p = 0.049$). In the T2DM patients, the level of other fecal bacteria correlated positively with the ALT ($r = 0.311$, $p = 0.011$), AST ($r = 0.258$, $p = 0.049$), and $\gamma$-GTP ($r = 0.300$, $p = 0.021$) levels, correlations that were not apparent in the control subjects.

The total SCFA level in the feces correlated negatively with the protein intake in the T2DM patients ($r = -0.275$, $p = 0.038$), a correlation that was not apparent in the control subjects. The fecal acetate level correlated negatively with the protein intake ($r = -0.285$, $p = 0.032$), insulin level ($r = -0.301$, $p = 0.005$), and with the HOMA-IR value ($r = 0.408$, $p = 0.001$), HOMA-IR value ($r = -0.325$, $p = 0.012$) levels. The level of fecal Prevotella spp. correlated negatively with the HbA1c level in the T2DM patients ($r = -0.271$, $p = 0.038$) and with the FFA level in the control subjects ($r = -0.258$, $p = 0.049$). In the T2DM patients, the level of other fecal bacteria correlated positively with the ALT ($r = 0.311$, $p = 0.011$), AST ($r = 0.258$, $p = 0.049$), and $\gamma$-GTP ($r = 0.300$, $p = 0.021$) levels, correlations that were not apparent in the control subjects.
positively with the γ-GTP ($r = 0.416$, $p = 0.001$) and TG ($r = 0.308$, $p = 0.037$) levels. In the control subjects, the fecal propionate level correlated negatively with the insulin level ($r = -0.284$, $p = 0.032$) and the HOMA-IR value ($r = -0.278$, $p = 0.036$) and it correlated positively with the γ-GTP ($r = 0.405$, $p = 0.002$) and ALT ($r = 0.292$, $p = 0.028$) levels. The fecal butyrate level correlated positively with the HDL-C level in the T2DM patients ($r = 0.303$, $p = 0.020$), a correlation that was not apparent in the control subjects. The fecal valerate level correlated negatively with the ALT level in the T2DM patients ($r = -0.298$, $p = 0.022$) and it correlated positively with the γ-GTP level in the control subjects ($r = 0.370$, $p = 0.004$). The fecal succinate level correlated positively with the TC ($r = 0.275$, $p = 0.036$) and FBG ($r = 0.304$, $p = 0.020$) levels, and with the total energy intake ($r = 0.316$, $p = 0.016$) in the control subjects, correlations that were not apparent in the T2DM patients.

**Discussion**

The main finding from this study was that the Japanese patients with T2DM had gut dysbiosis. Previous investigators have described gut dysbiosis in patients with T2DM of different races and this is the second study to compare the gut microbiota in Japanese patients with T2DM with that in aging and sex-matched healthy control individuals. The Japanese diet is very different from westernized diets, and the gut microbiota within Japanese patients with T2DM might differ from that in westernized individuals; therefore, it is important to investigate the differences between Japanese T2DM patients and healthy subjects in relation to the gut microbiota. The second major finding from this study comprised the differences between the T2DM patients and the healthy subjects regarding the relationships between the enteral environment, food intake, and the metabolic blood markers, and this is the first time that this has been described.

In the present study, the level of bacteria of the order *Clostridium* clust XI was significantly lower in the patients who were treated with metformin than that in the patients who were not treated with metformin (0.9 ± 3.6% vs 1.8 ± 3.2%, $p = 0.04$). The fecal level of the other bacteria was significantly higher in the patients who were treated with metformin than that in the patients who were not treated with metformin (18.5 ± 13.4% vs 9.7 ± 5.7%, $p = 0.009$). In the patients who were treated with α-GIs, the fecal levels of *Bifidobacterium* spp. (32.2 ± 10.3% vs 17.6 ± 13.7%, $p = 0.001$) and bacteria of the order *Lactobacillales* (27.1 ± 14.8% vs 10.3 ± 10.3%, $p = 0.001$) were significantly higher and the fecal levels of *Clostridium* cluster IV (3.8 ± 4.9% vs 9.8 ± 8.14%, $p = 0.008$), *Clostridium* subcluster XIVa (11.2 ± 8.8% vs 26.8 ± 11.6%, $p = 0.001$), and other bacteria (9.1 ± 5.9% vs 14.8 ± 11.0%, $p = 0.017$) were significantly lower than those in the patients those who were not treated with α-GIs.

The patients with T2DM had significantly lower levels of Bacteroides spp. than those in the control subjects, a finding that conflicts with the findings from studies involving Chinese and Japanese patients with T2DM. Qin et al. (29) reported that compared with control subjects, the fecal level of Bacteroides spp. was significantly higher in patients with diabetes, while Sato et al. (19) reported that there was no difference between patients with diabetes and control subjects regarding the level of Bacteroides spp. The reason for these differences is unclear, but dietary habits or the BMI might affect the levels of Bacteroides spp. The BMI of the patients with T2DM in this study was lower than that of the patients with T2DM in the study conducted by Sato et al. (19). The results from a recent study showed that Bacteroides and other commensal bacterial species affected the intestinal mucus and the glycocalyx, which may influence intestinal permeability. Further studies are needed to investigate the roles of Bacteroides spp. in T2DM.

In this study, the level of *Bifidobacterium* spp. was significantly higher in the patients with T2DM than that in the control subjects, which differs from the findings from previous studies. Sedighi et al. (24) reported that compared with control subjects, the level of *Bifidobacterium* spp. was significantly lower in patients with T2DM. Differences in relation to the analyses of the microbiota might explain the dissimilar findings. Sato et al. (19) reported that the level of *Bifidobacterium* did not differ between control subjects and patients with T2DM. α-GIs affect the gastrointestinal system, and they increase the levels of *Bifidobacterium* spp. and *Lactobacillus* spp. (19, 26, 27) In the present study, the levels of *Bifidobacterium* spp. and bacteria of the order *Lactobacillales* were higher in the patients with T2DM who were treated with α-GIs. The difference between the findings from this study and those from the study performed by Sato et al. (19) regarding the level of bacteria of the order *Lactobacillales* might be associated with the number of patients treated with α-GIs.

Sato et al. (19) reported that the total SCFA concentration in patients with T2DM was significantly lower than that in control subjects, which disagrees with the findings from the present study. Complex carbohydrates, such as those in dietary fiber, are metabolized into oligosaccharides and monosaccharides by the colonic microbiota, and they undergo fermentation to form SCFAs. Therefore, differences in relation to the uptake of carbohydrates by the study subjects might explain these divergent findings.

Acetate, propionate, and butyrate comprise 90–95% of the SCFAs present in the colon and the intraluminal SCFA concentrations consist of 60% acetate, 25% propionate, and 15% butyrate. SCFAs contribute approximately 5–10% of human energy requirements. In addition, SCFAs stimulate glucagon-like peptide-1 secretion via a G-protein-coupled receptor. In this study, the acetate and propionate levels correlated negatively with the level of insulin in the blood and the HOMA-IR value. Therefore, a decrease in the fecal propionate level may lead to glucose intolerance in T2DM patients.

In the present study, associations among the fecal microbiota, organic acids, and a variety of clinical parameters were identified. However, the associations in the T2DM patients and those in the control subjects were markedly different. This is supported by Inoue’s study which presented the difference of functional profile of microbiota between Japanese control subjects and T2DM patients from 16S rRNA metagenomic data. In addition, many associations between food intakes and the clinical parameters were identified in the patients with T2DM, but they were not apparent in the control subjects. Carbohydrate and protein intake were associated with fecal abundance of *Bifidobacterium* spp. and order *Lactobacillales* in T2DM patients but not in control subjects. The reasons for these differences are unclear, but they could suggest that the homeostasis among the gut microbiota and organs is disrupted in T2DM patients. Cani et al. (34) reported that a high-fat diet triggers gut dysbiosis and subsequently causes insulin resistance via a lipopolysaccharide-dependent mechanism. High-
fat food increased the translocation of live gram-negative bacteria through the intestinal mucosa and into the blood and mesenteric adipose tissue in mice, which was, in turn, linked to low-grade inflammation.\(^{(36)}\) Sato et al.\(^{(36)}\) reported that the level of interleukin-6, which was enhanced by lipoteichoic acid in a variety of cell types in other studies,\(^{(36)}\) was higher in patients with T2DM, and they detected gut bacteria in the blood of these patients. These changes might contribute to the disruption of organ homeostasis. Further studies are needed to investigate the mechanism underlying the relationships between the enteral environment and the clinical parameters.

The present study has some limitations. First, this study included a relatively small number of patients, and it was conducted at a single center. Further large-scale multicenter studies are needed to clarify the role of the gut microbiota in T2DM. Secondly, this study did not consider age-related changes in the gut microbiota. Age-related changes in the gut microbiota have been described in individuals aged >70 years, which included an increase in the level of Bacteroides spp.\(^{(37)}\) In this study, there was no relationship between age and the gut microbiota (data not shown), but this may have been a consequence of the small number of patients reducing the study’s analytical power. Further studies may be necessary to clarify the influence of age on the gut microbiota, and many more control subjects and T2DM patients will be required to determine the differences in gut dysbiosis with age.

**Conclusion**

Patients with T2DM have gut dysbiosis that may contribute to the onset of the disease and affect its prognosis. Furthermore, disturbances in the homeostasis of gut-related metabolism may underlie the pathogenesis of T2DM.

**References**

1. Neish AS. Microbes in gastrointestinal health and disease. *Gastroenterology* 2009; 136: 65–80.
2. Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygienic hypothesis expanded? *Diabetes Care* 2010; 33: 2277–2284.
3. Stumvoll M, Goldstein BJ, van Haareren TW. Type 2 diabetes: principles of pathogenesis and therapy. *Lancet* 2005; 365: 1333–1346.
4. Upadhyaya S, Banerjee G. Type 2 diabetes and gut microbiome: at the intersection of known and unknown. *Gut Microbes* 2015; 6: 85–92.
5. Rhodes CJ. Type 2 diabetes—a matter of beta-cell life and death? *Science* 2005; 307: 380–384.
6. Hoge CR, Feng L, Zephyr D, Stromberg AJ, Hennig B, Gaetke LM. Fruit and vegetable intake, as reflected by serum carotenoid concentrations, predicts reduced probability of polychlorinated biphenyl-associated risk for type 2 diabetes: National Health and Nutrition Examination Survey 2003–2004. *Nutr Res* 2014; 34: 285–293.
7. Shoeson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest* 2006; 116: 1793–1801.
8. Bucelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. *Acta Diabetologica* 2011; 48: 257–273.
9. Wing RR, Lang W, Wadden TA, et al. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care* 2011; 34: 1481–1486.
10. Takagi T, Naito Y, Inoue R, et al. Differences in gut microbiota associated with age, sex, and stool consistency in healthy Japanese subjects. *J Gastroenterol* 2019; 54: 53–63.
11. Wong JM, Jenkins DJ. Carbohydrate digestibility and metabolic effects. *J Nutr* 2007; 137(11 Suppl): 2539S–2546S.
12. Yamaguchi Y, Adachi K, Sugiyma T, et al. Association of intestinal microbial with metabolic markers and dietary habits in patients with type 2 diabetes.

**Acknowledgments**

We would like to thank Editage (www.editage.jp) for the English language editing.

**Abbreviations**

ALT alanine aminotransferase
AST aspartate aminotransferase
FBG fasting blood glucose
FFA free fatty acid
FFQ food frequency questionnaire
γ-GTP γ-glutamyl transferase
HbA1c glycated hemoglobin
HDLC high-density lipoprotein cholesterol
HOMA-IR homeostasis model of insulin resistance
LDL-C low-density lipoprotein cholesterol
OTU operational taxonomic units
SCFA short-chain fatty acid
T2DM type 2 diabetes mellitus
TC total cholesterol
TG triglyceride
T-RF terminal-restriction fragment
T-RFLP terminal-restriction fragment length polymorphism

**Funding**

None.

**Conflict of Interest**

K. Kasugai received research grants and lectures fees from AstAZeneca Co., Ltd., EA Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., and Takeda Pharmaceutical Co., Ltd. M. Sasaki received grants for joint research from Amano Enzyme I.

**Conflict of Interest**

K. Kasugai received research grants and lectures fees from AstraZeneca Co., Ltd., EA Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., and Takeda Pharmaceutical Co., Ltd. M. Sasaki received grants for joint research from Amano Enzyme I.
biota in adult patients with type 2 diabetes and healthy individuals. *Microb Pathog* 2017; **111**: 362–369.

24 Qin J, Li Y, Cai Z, *et al*. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* 2012; **490**: 55–60.

25 Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. *Clini Chem* 2013; **59**: 617–628.

26 Lee H, Ko G. Effect of metformin on metabolic improvement and gut microbiota. *Appl Environ Microbiol* 2014; **80**: 5935–5943.

27 Shin NR, Lee JC, Lee HY, *et al*. An increase in the *Akkermansia* spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* 2014; **63**: 727–735.

28 Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. *Nature* 2012; **489**: 242–249.

29 Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. *Scand J Gastroenterol Suppl* 1996; **216**: 132–148.

30 Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* 2001; **81**: 1031–1064.

31 McNeil NL. The contribution of the large intestine to energy supplies in man. *Am J Clin Nutr* 1984; **39**: 338–342.

32 Tolhurst G, Heffron H, Lam YS, *et al*. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. *Diabetes* 2012; **61**: 364–371.

33 Inoue R, Ohue-Kitano R, Tsukahara T, *et al*. Prediction of functional profiles of gut microbiota from 16S rRNA metagenomic data provides a more robust evaluation of gut dysbiosis occurring in Japanese type 2 diabetic patients. *J Clin Biochem Nutr* 2017; **61**: 217–221.

34 Cani PD, Amar J, Iglesias MA, *et al*. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 2007; **56**: 1761–1772.

35 Amar J, Burcelin R, Ruidavets JB, *et al*. Energy intake is associated with endotoxemia in apparently healthy men. *Am J Clin Nutr* 2008; **87**: 1219–1223.

36 Tang CH, Hsu CJ, Yang WH, Fong YC. Lipoteichoic acid enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, PKCdelta and c-Src dependent pathways. *Biochem Pharmacol* 2010; **79**: 1648–1657.

37 Odamaki T, Kato K, Sugahara H, *et al*. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. *BMC Microbiol* 2016; **16**: 90.